Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...

The new drug, amycretin, similar to the company's blockbuster weight-loss and diabetes drugs Wegovy and Ozempic ... on 125 ...

Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the ...

Junshi has conducted more than 40 company-sponsored clinical studies of the therapy. Credit: PeopleImages.com – Yuri A/Shutterstock. Shanghai Junshi Biosciences and its subsidiary TopAlliance ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular semaglutide medicines as one of the 15 additional drugs covered under Medicare Part ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...

Patients who took triple the normal dose of semaglutide, the main ingredient in Wegovy, for 72 weeks lost 20.7% of their body weight, Novo said Friday in a statement . That compared with a 17.5% ...

Patients who took triple the normal dose of semaglutide, the main ingredient in Wegovy, for 72 weeks lost 20.7% of their body weight, Novo said Friday in a statement. That compared with a 17.5% ...

Fol­low­ing the poor­er-than-hoped per­for­mance of Ca­griSe­ma last month, No­vo Nordisk need­ed an em­phat­ic clin­i­cal suc­cess with its high-dose ver­sion of We­govy. The … ...